Lipid GVS-18-B6
Instructions for Use
Product information
GVS-18-B6 is a biodegradable silicon-ether ionizable lipid reported for liver-directed mRNA delivery. The literature-verified structure contains a dimethylamino headgroup connected through a four-carbon linker to a silicon center bearing three cis-4-decenyl ether chains. In the cited study, GVS-18-B6 LNPs showed high mRNA encapsulation, an apparent LNP pKa of 6.15, preferential hepatic expression after intravenous administration, rapid tissue clearance, and favorable tolerability in the reported mouse and nonhuman-primate experiments. All formulation and performance values shown below are literature-reported study results, not specifications or guaranteed performance of the supplied lipid.
| CAS No. | Not available |
| Chemical Name | Lipid GVS-18-B6 |
| Formula | C36H71NO3Si |
| M.Wt | 594.05 |
| Purity | ELSD-HPLC>95% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
Formulation & study context
Literature information refers to the cited study and its particular formulation. Administration routes are research context, not clinical instructions or a guarantee of performance.
| Component | mol% | Role |
|---|---|---|
| GVS-18-B6 | 54.6 | Ionizable lipid |
| DSPC | 10.9 | Helper phospholipid |
| Cholesterol | 32.8 | Sterol |
| PEG-conjugated lipid (identity not specified in article) | 1.6 | PEG lipid |
| Reported total | 99.9 | Source values retained |
| N/P ratio | Not reported in the cited article |
| Buffer & pH | Nucleic acid in acetate buffer, pH 5; final LNP in Tris-sucrose buffer, pH 8.0 |
| Cargo | EGFP mRNA |
| Administration route | Intravenous injection (IV) |
| Dose | 0.5 mg mRNA/kg, single dose |
| Animal model | Female BALB/c mice, 7-8 weeks old |
| Formulation process | Controlled mixing of the aqueous nucleic-acid phase with an ethanolic four-lipid solution, followed by tangential-flow ultrafiltration, buffer exchange, concentration and 0.2 µm sterile filtration |
N/P is the molar ratio of specified lipid nitrogen groups to nucleic-acid phosphate groups. A lipid:cargo mass ratio is a different quantity and must not be used as N/P.
Stock-solution preparation table
Calculated from the product-page molecular weight: 594.05 g/mol. Volumes are final solution volumes.
| Lipid mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | 16.834 mL | 3.367 mL | 1.683 mL |
| 25 mg | 42.084 mL | 8.417 mL | 4.208 mL |
| 50 mg | 84.168 mL | 16.834 mL | 8.417 mL |
| 100 mg | 168.336 mL | 33.667 mL | 16.834 mL |
| 250 mg | 420.840 mL | 84.168 mL | 42.084 mL |
Volume (mL) = mass (mg) × 1000 / [MW (g/mol) × concentration (mM)]. These are mathematical conversions, not measured solubility or validated solvent recommendations. Confirm solvent compatibility and the molecular weight of the exact material before use.
Open editable solution calculators →Handling & storage
Provided that storage conditions are as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 1 year.
Wherever possible, prepare and use solutions on the same day. If stock solutions must be prepared in advance, store them as aliquots in tightly sealed vials at -20°C. Generally, these will be usable for up to one month.
Before use, and prior to opening the vial, allow the product to equilibrate to room temperature for at least 1 hour.
References
Cited literature for this formulation and performance dataset Holland R, Lam K, Jeng S, et al. Silicon Ether Ionizable Lipids Enable Potent mRNA Lipid Nanoparticles with Rapid Tissue Clearance. ACS Nano. 2024;18:10374-10387. DOI: 10.1021/acsnano.3c09028 Formulation: p. 10375 and Materials & Methods; performance: Table 1 and Figures 2-6.